<DOC>
	<DOCNO>NCT00116935</DOCNO>
	<brief_summary>In study , patient diagnose gastrointestinal stromal tumor ( GIST ) randomly allocate 1:1 ratio receive imatinib ( Gleevec ) either 12 36 month follow surgery . The study participant require histologically verified GIST high risk GIST recurrence despite complete removal macroscopic GIST tissue surgery . The high/very high risk recurrence define one following : 1 ) large tumor diameter 10 cm ; 2 ) mitosis count high ( 10 mitoses per 50 high power microscope field , HPFs ) ; 3 ) large tumor diameter 5 cm mitosis count 5/50 HPFs ; 4 ) tumor spillage take place abdominal cavity time surgery follow spontaneous tumor rupture . All study participant receive imatinib 400 mg/day orally , duration imatinib administration determine randomly ( either 12 36 month ) . The study participant follow use blood test compute tomography ( MRI ) abdomen . The computed tomography examination perform 6 month interval median 5 year . A total 280 patient enter study . The study hypothesis adjuvant imatinib may prevent GIST recurrence , may difference rate GIST recurrence two group .</brief_summary>
	<brief_title>Study Comparing 12 Months Versus 36 Months Imatinib Treatment Gastrointestinal Stromal Tumor ( GIST )</brief_title>
	<detailed_description>This open-label , randomize , prospective , phase III , multicenter study carry Nordic country Germany . Following macroscopically complete surgery , study participant allocate receive imatinib either 12 36 month . At randomization , patient stratify 2 stratum : 1 ) local disease ( 1 GIST tumor ) ; 2 ) intra-abdominal implant resectable intra-abdominal/hepatic metastasis , intra-abdominal spillage present , R1 surgery carry ( microscopic disease leave behind ) . The imatinib dose 400 mg/day administer food . Imatinib dose adjustment make per protocol . Medical history , current medication , weight , height , ECOG performance status record prior study entry . Physical examination , blood cell count , blood biochemistry , pregnancy test , chest X-ray CT , CT MRI abdomen pelvis carry out/measured prior study entry . FDG-PET optional staging examination . Research serum sample collect bank prior initiate imatinib 6-month interval study . Tumor tissue review centrally confirm histological diagnosis GIST , KIT PDGFRA gene mutation analysis perform stored GIST tissue . The study participant monitor adjuvant treatment follow adjuvant treatment . Physical examination , weight ECOG performance status assess 4- 26-week interval . Adverse event collect use structure form time evaluation visit . Blood cell count blood biochemistry measure 2- 6-week interval imatinib therapy , 6-month interval follow completion adjuvant therapy . CT MRI examination abdomen pelvis perform 6-month interval study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age 18 old Histologically document diagnosis GIST Resectable GIST GIST remove open surgery Immunohistochemical documentation GIST ( immunostaining KIT/CD117 ) High risk tumor recurrence define one following : 1 ) large tumor diameter great 10.0 cm ( measure pathologist , mitotic count ) ; 2 ) mitotic count 10 mitoses per 50 high power field ( HPFs ) ( tumor size ) ; large tumor diameter large 5.0 cm mitotic count 5/50 HPFs ; 4 ) tumor spillage abdominal cavity surgery ( tumor rupture ) . No residual tumor must present laparotomy , postoperative CT MRI examination . Patients microscopically infiltrate margin ( suspected microscopical infiltration , R1 ) also allow enter study . Performance status 0 , 1 , 2 ( ECOG ) Adequate organ function , define follow : total bilirubin &lt; 1.5 x ULN ( upper limit normal ) , serum AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 x ULN , creatinine &lt; 1.5 x ULN , ANC ( neutrophil count ) &gt; 1.5 x 10^9/L , platelet &gt; 100 x 10^9/L . Negative pregnancy test ( female childbearing potential ) Written , voluntary inform consent Inoperable metastatic GIST Less 1 week 12 week elapse surgery Recurrent GIST Patient receive investigational agent within 28 day calculate first day study drug dose Patient le 5 year free another primary malignancy Patient grade III/IV cardiac problem define New York Heart Association Criteria Female patient pregnant breastfeed Patient severe uncontrolled medical disease ( i.e . uncontrolled diabetes , severe chronic renal disease , active uncontrolled infection ) . Concurrent use warfarin acetaminophen allow imatinib . Chronic liver disease Known diagnosis human immunodeficiency virus ( HIV ) infection Patient receive chemotherapy GIST Patient receive neoadjuvant imatinib therapy prior randomization Radiotherapy 25 % bone marrow Patient significant history noncompliance medical regimen inability grant reliable informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Gastrointestinal stromal tumor</keyword>
	<keyword>GIST</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Adjuvant therapy</keyword>
	<keyword>KIT</keyword>
	<keyword>PDGFRA</keyword>
	<keyword>Receptor tyrosine kinase</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
</DOC>